Document Classification

Section Type: RESULTS

Text: In the efficacy cohort, the infarct size did not differ between groups on either the first CMR scan (n = 136 ; 15. 8 % LV mass [95 % confidence interval { CI }, 13. 3-18. 2 % LV mass] for the epoetin alfa group vs 15. 0 % LV mass [95 % CI, 12. 6-17. 3 % LV mass] for the placebo group ; P =. 67) or on the second CMR scan (n = 124 ; 10. 6 % LV mass [95 % CI, 8. 4-12. 8 % LV mass] vs 10. 4 % LV mass [95 % CI, 8. 5-12. 3 % LV mass], respectively ; P =. 89).